NEW HALO DISINFECTION SYSTEM APPROVED BY EPA FOR WHOLE ROOM DISINFECTION DRAMATICALLY LOWERS HEALTHCARE-ACQUIRED C. DIFF INFECTION RATES
WILMINGTON, DE (February 25, 2014) ---- Sanosil International, manufacturer and marketer of room and surface disinfectants and industrial biocides, today launched the Halo Disinfection System™, which eliminates 99.9999% of Clostridium difficile (C. diff) spores in entire rooms. The Halo Disinfection System is registered with the United States Environmental Protection Agency (EPA Registration No. 84526-6). It is the first disinfectant fogging system validated by the EPA to kill C. diff spores.
The Halo Disinfection System™ also kills many other pathogens typically found in hospitals and healthcare environments using a patented solution of hydrogen peroxide and ionic silver applied in a dry mist by a cost-effective portable fogger.
The Halo Disinfection System (HDS) incorporates the HaloFogger™ using the healthcare-grade HaloMist™ solution. The system is an easy-to-use, economic and highly effective alternative to “spray & wipe”, UV light and other disinfecting strategies. During hands-free use, the HaloFogger converts the HaloMist into a clear, odorless dry mist that reaches in and around every surface in an enclosed area. There is no need to mix the solution, nor is there any need for rinsing or wiping.
After application, HaloMist decomposes into water and oxygen molecules, dries on contact and does not harm sensitive medical equipment. The system does not contain or produce chlorine, hypochlorite (bleach), alcohol, aldehydes, phenols, ammonium compounds or sodium hydroxide. These toxins and harsh chemicals can be found in many other disinfecting solutions.
Halo Disinfection System Effective Against Stubborn C. Diff Infections
In practical use, the Halo Disinfection System™ has been demonstrated effective against a wide range of pathogens, including the highly stubborn C. diff pathogen, one of America’s leading causes of healthcare-acquired infections (HAIs).
During a recent study of the HDS system at Pennsylvania Hospital, a 496-bed urban teaching hospital in Philadelphia, PA, infection control experts cut the rate of C. diff infections by 66% after deploying the HDS system in patient rooms, operating rooms and treatment areas.
In a similar study, Southwestern Vermont Medical Center experienced a period of more than 6 months without a single hospital-acquired C. diff case.
These results suggest that the system offers a comparatively simple, inexpensive way to comply with a federal mandate to reduce C. diff HAI infections 30% by 2016.
C. diff infections remain stubbornly high even as incidences of other types of HAIs are declining, according to the Centers for Disease Control (CDC). Patients infected with C. diff suffer severe diarrhea and dehydration and as many as 30,000 Americans die each year from C. diff-related infections, about the same number as die in auto accidents.
For Sanosil International
Sue St. Laurent
About Sanosil International
Sanosil International is a privately held company based in New Castle, Delaware. Sanosil International maintains the exclusive manufacturing and marketing rights for Sanosil biocide for much of the world, secured from the inventor and international patent holder, Sanosil Limited of Switzerland. The efficacy of Sanosil products is endorsed by customers worldwide and supported by over 200 independent tests and numerous government approvals.
The Sanosil formula is based on a unique stabilization process that blends hydrogen peroxide and ionized silver to create a broad-spectrum solution for killing germs. Sanosil International’s Halo Disinfection System has been approved by the United States Environmental Protection Agency for whole room disinfection.
More information can be found at www.sanosilinternational.com